Hims & Hers Canada Expansion Targets Weight Loss

Hims & Hers Health, Inc. (NYSE: HIMS) completed an all-cash acquisition of Canadian telehealth provider Livewell and plans to launch a Canadian weight-loss program in 2026 timed to the expected arrival of generic semaglutide, expanding its GLP-1 strategy.

Acquisition and Market Entry

Hims & Hers completed the Livewell acquisition, a Canadian digital health and telehealth provider focused on weight loss and wellness services, the company said in a press release. The purchase marks Hims & Hers’ formal entry into Canada, where it will initially focus on digital weight-loss programs and related healthcare services.

The company has appointed Canadian-based management and an obesity-focused chief medical officer to oversee local operations as part of its integration plan. Canada joins Hims & Hers’ existing U.S. and European markets in a broader international expansion strategy. Management said the Canadian platform is designed to be scalable, allowing the company to extend virtual care into other specialties over time.

Weight-Loss Program and Timing

Hims & Hers is developing a comprehensive weight-management program for Canada that will combine clinician oversight, coaching, digital tools, and medication options aligned with clinical protocols. The program will integrate GLP-1 agonists, specifically anticipating the availability of generic semaglutide to improve affordability and access.

The company plans to launch the program in 2026, coinciding with the expected arrival of the first generic semaglutide products in Canada. Management views this timing as a commercial catalyst that could broaden the addressable market and improve unit economics compared with branded GLP-1 therapies. The move strengthens Hims & Hers’ broader GLP-1 and obesity-care strategy by establishing a local operating base and clinical leadership to deploy virtual, subscription-style programs when generics enter the market.